Cargando…
The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
Histone deacetylases (HDACs) are master regulators of chromatin remodeling, acting as epigenetic regulators of gene expression. In the last decade, inhibition of HDACs has become a target for specific epigenetic modifications related to cancer development. Overexpression of HDAC has been observed in...
Autores principales: | Cosenza, Maria, Pozzi, Samantha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121661/ https://www.ncbi.nlm.nih.gov/pubmed/30096875 http://dx.doi.org/10.3390/ijms19082337 |
Ejemplares similares
-
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine
por: Cosenza, Maria, et al.
Publicado: (2017) -
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination
por: Cosenza, Maria, et al.
Publicado: (2020) -
Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
por: Thomas, Elizabeth A.
Publicado: (2014) -
HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases
por: Yoon, Somy, et al.
Publicado: (2019) -
HDAC Inhibitors: Innovative Strategies for Their Design and Applications
por: Daśko, Mateusz, et al.
Publicado: (2022)